

Written Agreement with External Author (Author Master Agreement)

Dear Therese Svendsen:

AbbVie Inc. (“**AbbVie**”) applies robust ethical practices to all AbbVie publications. This Author Master Agreement (“**Agreement**”) describes AbbVie’s practices for publications originated or managed by AbbVie (each a “**Publication**”). By signing this Agreement, you confirm your commitment to upholding AbbVie’s publishing practices when participating as an author on Publications with AbbVie during the next thirty-six (36) months, beginning on the date you sign this agreement and ending thirty-six (36) months later. AbbVie will also provide you with a confirmation letter regarding your participation as an author on each Publication. When this Master Agreement expires or is otherwise terminated, the terms of this Master Agreement shall continue to apply to all Publications initiated under this Agreement, before the date of expiration or termination, until such Publications are completed.

Requirements for Authorship

AbbVie follows the requirements for authorship set forth by the International Committee of Medical Journal Editors (ICMJE). If you agree to be an author on any Publication, you agree that for each Publication you will follow the ICMJE criteria for authorship in effect at the time of such Publication. Current ICMJE authorship criteria require each author of a Publication to:

- Substantially contribute to the conception and design, or acquisition of the data, or analysis and interpretation of the data; and
- Draft the Publication or revise it critically for important intellectual content; and
- Approve the final version to be submitted for publication; and
- Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Transparency Disclosures

In the interest of ensuring transparency, you agree to submit the following disclosures to AbbVie and to the congress and/or journal, as applicable:

- Any financial, professional, or personal relationship that might reasonably be perceived as a conflict of interest;
- Your relationship with AbbVie;
- The role of AbbVie, including any role in the study design, research, analysis, data collection, and/or interpretation of data, as well as writing, reviewing, and/or approving the Publication;
- Any disclosure requirements from any health care institution, committee, medical or scientific organization with which you are affiliated; and
- Any individuals who need to be acknowledged, including individuals who provided medical writing, editorial, or other technical assistance, and the funding source for their involvement, as applicable. (Please note that written permission to be acknowledged will need to be provided by each individual.)

Access to Information; Balanced and Timely Publication

As an author, you will be provided access to materials and related information needed to prepare the Publication. You agree that any Publication will present information in a balanced manner. For purposes of this Agreement, “balanced” means in a manner that (i) presents accurate and non-misleading information as to study, analysis, data, or results, including any findings relating to safety and/or efficacy

This information is confidential to AbbVie. The user is responsible for using the appropriate version of this document.

Written Agreement with External Author (Author Master Agreement)

of any compounds, and (ii) does not exclude or downplay negative safety or health information. You agree to adhere to established timelines for development of the Publication.

Privacy

You agree not to publish any personally identifiable information of any patients or study subjects without (i) the applicable patients' or study subjects' written consent, which you agree to provide to AbbVie, and (ii) AbbVie's written consent.

Confidentiality

You agree (i) to not disclose or use information, data, protocols, or other materials provided to you by AbbVie in connection with a Publication that are not publicly available (collectively, "Confidential Information") except for the purpose of preparing and submitting Publications; (ii) if applicable, your employees or agents who need access to the Confidential Information will abide by the same confidentiality obligations described in this Agreement; (iii) to return or destroy all Confidential Information related to the Publication, including anything confidential that you have developed in the course of preparing the Publication, upon AbbVie's request or when the Publication has been completed; however, you may retain one copy of Confidential Information in your confidential files for archival purposes only; and (iv) to contact AbbVie immediately if any third party seeks Confidential Information from you.

Confidential Information shall not include information that you can demonstrate by your written records: (a) has become part of the public domain through no fault of yours; (b) you already possessed prior to disclosure by AbbVie; (c) you learned from a third party who had no duty of confidentiality to AbbVie; or (d) you independently develop without use of or reference to the Confidential Information. These obligations of confidentiality shall continue for a period of seven (7) years after the expiration or termination of this Agreement.

You agree not to use the name, trademark, service mark or logo of AbbVie or AbbVie's affiliates in any publicity, advertising or other information intended to be used for commercial or promotional purposes without AbbVie's prior written consent.

Copyright

If required for AbbVie to submit the Publication to the applicable journal and/or congress, you agree to directly assign to the applicable journal and/or congress your copyrights in the Publication. You hereby agree that AbbVie may, after the Publication becomes public, distribute the Publication to third parties at its sole discretion.

Compensation and Reimbursement

In accordance with standard industry best publishing practices, AbbVie does not compensate authors for their involvement with publication development (e.g., time spent drafting, reviewing, and/or revising the proposed Publications), or presentations that occur at medical/scientific congresses (e.g., oral or poster presentations). Reasonable and necessary out-of-pocket expenses incurred may be reimbursed, provided you: (i) obtain AbbVie's written approval before expense is incurred, and (ii) submit appropriate receipts and reimbursement form.

This information is confidential to AbbVie. The user is responsible for using the appropriate version of this document.

Written Agreement with External Author (Author Master Agreement)

Debarment

By signing this agreement, you confirm that you have not been and are not the subject of an action or proceeding that could lead to you becoming a debarred entity or individual, an excluded entity or individual, or a convicted entity or individual (as described in 21 USC §335(a) and 42 USC 1320a - 7(a)) nor are you listed on the FDA's disqualified/restricted list or otherwise disqualified or restricted as an FDA investigator. You agree to notify AbbVie immediately if you receive notice that you might be debarred, excluded, convicted, or disqualified/restricted as described in this paragraph.

Signature

We, at AbbVie, appreciate your commitment to an open and transparent publication process. Please sign this Agreement to indicate that you agree to participate as an author and agree to meet all of the requirements specified in this Agreement. If you have any questions, please contact your AbbVie publication representative.

THERESE SVENDSEN

Author's Printed Name

Therese Svendsen

Author's Signature

09

Month

20

Day

2016

Year

This information is confidential to AbbVie. The user is responsible for using the appropriate version of this document.